Drug intelligence / Profile preview

ReJoin

Development stage: Unknown
Lead developer: AbelZeta, Inc.
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intraarticular

Overview

ReJoin is an allogeneic stem cell therapy consisting of human adipose tissue-derived mesenchymal progenitor cells (haMPCs). Developed by AbelZeta (formerly Cellular Biomedicine Group), it is specifically designed for the treatment of knee osteoarthritis. The therapy is administered via intra-articular injection and functions as an "off-the-shelf" biologic product. Its therapeutic mechanism involves the use of mesenchymal progenitor cells to suppress local inflammation and facilitate the repair of damaged cartilage within the knee joint, aiming to alleviate pain and restore function in patients with degenerative joint disease.

Brand names: ReJoin
Other names: Allogenic Adipose Tissue-Derived Mesenchymal Progenitor CellsAllogenic Adipose Tissue-Derived Mesenchymal Progenitor Cells Therapy

Beyond the preview

Go deeper on ReJoin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ReJoin.

Explore the full profile